The Medicare GLP-1 Bridge Program is more than a temporary access initiative – it represents a pivotal moment in chronic disease management.
Starting July 1, 2026, CMS will launch the GLP-1 Bridge Program, a temporary initiative providing eligible Medicare Part D beneficiaries with access to GLP-1 weight-loss therapies through December 31, 2027.
While the program is limited in duration, its impact could extend far beyond the pilot period. Utilization trends, adherence patterns, and clinical outcomes generated during the program are likely to influence future policy, reimbursement models, and long-term approaches to obesity management within Medicare.
What Are GLP-1 Medications?
GLP-1 (glucagon-like peptide-1) medications were originally developed to treat type 2 diabetes and are now FDA-approved for chronic weight management in adults with obesity. Common examples include semaglutide and tirzepatide, marketed under brands such as Wegovy and Zepbound.
Under current Medicare rules, coverage for GLP-1 medications is generally limited to diabetes or certain cardiovascular indications. The CMS Bridge Program creates a separate, temporary pathway for eligible beneficiaries to access select GLP-1 medications for weight loss at a predictable cost.
How the CMS Bridge Program Works
The CMS bridge program is a national pilot that provides qualifying Medicare Part D beneficiaries with access to FDA-approved weight-loss GLP-1s between July 1, 2026, and December 31, 2027. It operatesoutside the standard Part D benefit. Part D sponsors do not carry drug risk for covered products under this pilot, and members do not need their plan to opt in.
CMS uses a central processor to manage prior authorization, claims adjudication, and pharmacy payment. Covered drugs include approved GLP-1s for weight loss, currently Wegovy (injection and tablets), Zepbound (KwikPen), and other FDA-labeled agents as announced. Beneficiaries pay a fixed $50 copayment per 30-day supply—far lower than typical retail prices. When the pilot ends, members transition to standard Medicare rules or to the BALANCE Model as implemented.
Why Demand Will Surge
The Medicare GLP-1 Bridge Program is expected to significantly increase demand for weight management therapies across the Medicare population.
Several factors are expected to drive this increase:
- Reduced cost barriers. Beneficiaries who may previously have faced costs of approximately $1,000 per month can access covered therapies through the program for a fixed $50 copayment per 30-day supply.
- Expanded eligibility. The program includes individuals with obesity and certain qualifying comorbidities, increasing the number of members eligible for treatment.
- Growing awareness. Increased media attention and provider confidence surrounding GLP-1 therapies are likely to drive additional member inquiries and prescription requests.
For Medicare Advantage organizations, this creates both an operational challenge and a strategic opportunity. Even without direct drug-cost exposure during the pilot period, utilization patterns established today may influence future reimbursement structures, care models, and clinical management requirements.
Organizations that proactively prepare for increased member and provider demand will be best positioned for success.
How Shearwater Helps Organizations Prepare
Shearwater Health helps plans, providers, and care management teams navigate the operational demands of the GLP-1 Bridge Program while maintaining quality, compliance, and cost control.
Our support includes:
- Channeling appropriate utilization through established clinical workflows
- Managing member and provider call volume related to the GLP-1 Bridge Program
- Providing member and provider education on program requirements and prior authorization processes
- Processing prior authorization requests and supporting documentation
- Coordinating care and enrolling eligible members in care management, condition management, and lifestyle management programs
- Supporting adherence, monitoring, and ongoing member engagement
- Delivering reporting and operational insights to prepare organizations for post-pilot utilization management
Why Acting Now Matters
The Medicare GLP-1 Bridge Program creates a limited window for organizations to prepare for a new era of obesity and chronic disease management. As demand for GLP-1 therapies continues to grow, health plans and provider organizations that proactively establish workflows, educate members and providers, and build scalable support models will be best positioned for long-term success.
Waiting until utilization spikes can lead to operational strain, increased call volumes, authorization backlogs, fragmented member experiences, and missed opportunities to influence future care strategies.
Shearwater Health’s global clinical workforce provides a scalable, cost-efficient, and clinically aligned solution to help organizations prepare for increased demand while maintaining quality, compliance, and cost control. From utilization management and prior authorization support to member education and care coordination, we help organizations navigate the GLP-1 Bridge Program with confidence today while building readiness for what’s next.
Ready to prepare for increased GLP-1 demand? Contact Shearwater Health to learn how our clinical support teams can help your organization scale efficiently while delivering a high-quality member experience.
